ZenNews› Health› AI Virus Design Splits U.S. Biotech Funding Calcu… Health AI Virus Design Splits U.S. Biotech Funding Calculus Synthetic pathogen breakthroughs force investors to weigh profit against biosafety risk By Oliver Walsh Aug 11, 2026 1 min read Updated: Aug 11, 2026 Share Share X Facebook WhatsApp Copy link How do you feel about this? 🔥 0 😲 0 🤔 0 👍 0 😢 0 Health Virus Design Splits Biotech O Oliver Walsh Health & Climate Oliver Walsh analyses medical research, US health policy and climate science. You might also like › Health mRNA Cancer Vaccine Trial Stirs U.S. Biotech Investment Rush 01 Sep 2026 Economy AI Energy Shock Risk Splits Fed and White House Advisers 31 Aug 2026 Health Pig Kidney Record Puts Xenotransplant Policy in Congress 08 Sep 2026 Health Pig Kidney Milestone Shifts U.S. Transplant Donor Debate 08 Sep 2026 Health Black Market Retatrutide Floods U.S. as FDA Approval Lags 07 Sep 2026 Health FDA Weighs Urine Cancer Test That Rivals Invasive Methods 03 Sep 2026 Also interesting › Society War Readiness Rhetoric Exposes Gaps in US Mental Health Prep 20 hrs ago Economy AI Giants' Merch Lines Test Silicon Valley Brand Strategy Yesterday World Fed's Unanimous Hike Defies Trump, Tests Bank Independence Yesterday Tech Altman's 'Trust Us' Pitch Meets Skepticism on Capitol Hill 16 Sep 2026 More in Health › Health Weight-Loss Drug Shortage Fuels Counterfeit Crisis Across U.S. 11 Sep 2026 Health FDA Eyes Hot Beverage Cancer Link as Labeling Gap Widens 11 Sep 2026 Health Hot Beverage Warning Puts FDA's Labeling Rules in Spotlight 10 Sep 2026 Health Pig Kidney Record Puts Xenotransplant Policy in Congress 08 Sep 2026 ← Health AI-Designed Viruses Prompt Senate Biosecurity Alarm Health → FDA's New Weight-Loss Pill Reshapes U.S. Obesity Drug Market
